USP7 and liver cancer: Inhibition of the USP7 by P5091 disrupts a positive feedback loop involving PRDM1-mediated upregulation of FGL1, thereby enhancing CD8+ T cell activity and suppressing liver cancer growth; combined USP7 and LAG3 blockade demonstrates superior antitumor efficacy compared to LAG3 inhibition alone [132].